发行股份购买资产并募集配套资金 桂林莱茵生物科技股份有限公司 证券代码：002166 证券简称：莱茵生物 上市地点：深圳证券交易所 暨关联交易预案 | 项目 | 交易对方 | | --- | --- | | 发行股份购买资产 | 德福金康普控股有限合伙企业、厦门德福金普 | | | 投资合伙企业（有限合伙） | | 募集配套资金 | 广州德福营养投资合伙企业（有限合伙） | 二〇二五年十二月 桂林莱茵生物科技股份有限公司 发行股份购买资产并募集配套资金暨关联交 上市公司声明 本公司及全体董事、高级管理人员保证本预案内容及其摘要内容的真实、 准确、完整，不存在虚假记载、误导性陈述或重大遗漏。如因提供的信息、出 具的说明及确认存在虚假记载、误导性陈述或重大遗漏，给投资者造成损失的， 将依法承担相应法律责任。 本公司控股股东、董事、高级管理人员承诺：如本次交易所提供的信息涉 嫌虚假记载、误导性陈述或者重大遗漏，被司法机关立案侦查或者被中国证券 监督管理委员会立案调查的，在形成调查结论以前，不转让在上市公司拥有权 益的股份，并于收到立案稽查通知的两个交易日内将暂停转让的书面申请和证 券账户提交上市公司董事会，由董事会 ...

桂林莱茵生物科技股份有限公司董事会 关于本次交易是否构成重大资产重组、关联交易 及重组上市的说明 桂林莱茵生物科技股份有限公司（以下简称"公司"）拟向德福金康普控股有 限合伙企业（以下简称"德福金康普"）和厦门德福金普投资合伙企业（有限合伙） （以下简称"厦门德福金普"）发行股份购买其合计持有的北京金康普食品科技有 限公司 80%股权，同时向广州德福营养投资合伙企业（有限合伙）（以下简称"广 州德福营养"）发行股份募集配套资金（以下简称"本次交易"）。 根据《上市公司重大资产重组管理办法》《深圳证券交易所股票上市规则》等 相关规定，公司董事会就本次交易是否构成关联交易、重大资产重组及重组上市进 行了审慎判断，并说明如下： 一、本次交易预计不构成重大资产重组 本次交易的审计及评估工作尚未完成，标的公司估值及定价尚未确定，本次交 易预计不能达到《上市公司重大资产重组管理办法》规定的重大资产重组标准。对 于本次交易是否构成重大资产重组的具体认定，公司将在重组报告书中予以详细分 析和披露。本次交易涉及发行股份购买资产，因此需通过深圳证券交易所审核，并 待中国证券监督管理委员会注册后方可实施。 桂林莱茵生物科技股份有限 ...

2、最近一年财务报表的编制和披露在重大方面不符合企业会计准则或者相关信 息披露规则的规定；最近一年财务会计报告被出具否定意见或者无法表示意见的审 计报告；最近一年财务会计报告被出具保留意见的审计报告，且保留意见所涉及事 项对上市公司的重大不利影响尚未消除。本次发行涉及重大资产重组的除外； 3、现任董事、高级管理人员最近三年受到中国证监会行政处罚，或者最近一年 受到证券交易所公开谴责； 4、公司或者其现任董事、高级管理人员因涉嫌犯罪正在被司法机关立案侦查或 者涉嫌违法违规正在被中国证监会立案调查； 桂林莱茵生物科技股份有限公司 桂林莱茵生物科技股份有限公司董事会 关于本次交易符合《上市公司证券发行注册管理办法》 第十一条规定的说明 桂林莱茵生物科技股份有限公司（以下简称"公司"）拟向德福金康普控股有 限合伙企业和厦门德福金普投资合伙企业（有限合伙）发行股份购买其合计持有的 北京金康普食品科技有限公司 80%股权，同时向广州德福营养投资合伙企业（有限 合伙）发行股份募集配套资金（以下简称"本次交易"）。 根据《上市公司证券发行注册管理办法》的要求，结合本次交易各方签订的《控 制权变更框架协议》《股份转让协议》《表 ...

莱茵生物公告，公司控股股东、实际控制人秦本军与广州德福营养签署《控制权变更框架协议》《股份 转让协议》《表决权放弃协议》，约定秦本军向广州德福营养协议转让其所持公司6000万股股份，占公 司总股本8.09%，并放弃1.89亿股股份表决权，保留2224.83万股股份表决权。交易完成后，广州德福营 养将成为公司控股股东，侯明和LI ZHENFU将成为公司共同实际控制人。 ...

桂林莱茵生物科技股份有限公司 证券代码：002166 证券简称：莱茵生物 公告编号：2025-078 桂林莱茵生物科技股份有限公司 关于暂不召开股东会的公告 根据《上市公司重大资产重组管理办法》《上市公司证券发行注册管理办法》 《上市公司监管指引第 9 号——上市公司筹划和实施重大资产重组的监管要求》 《深圳证券交易所上市公司重大资产重组审核规则》等相关法律法规和规范性文 件的要求，本次交易尚需深圳证券交易所审核通过及中国证券监督管理委员会同 意注册后方可实施。 鉴于本次交易标的资产的审计、评估等工作尚未完成，基于本次交易相关工 作的整体安排，公司董事会决定暂不召集股东会审议本次交易相关事项。待与本 次交易相关的审计、评估等工作完成后，公司将另行召开董事会审议本次交易的 相关事项，并依照法定程序召开股东会审议本次交易的相关事宜。 特此公告。 桂林莱茵生物科技股份有限公司董事会 二〇二五年十二月二十四日 1 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 桂林莱茵生物科技股份有限公司（以下简称"公司"）于 2025 年 12 月 22 日召开第七届董事会第十次会 ...

桂林莱茵生物科技股份有限公司 证券代码：002166 证券简称：莱茵生物 公告编号：2025-074 桂林莱茵生物科技股份有限公司 第七届董事会第十次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 桂林莱茵生物科技股份有限公司（以下简称"公司"） 关于召开第七届董事 会第十次会议的通知于 2025 年 12 月 18 日以短信、即时通讯工具及电子邮件的方 式发出，会议于 2025 年 12 月 22 日下午 14：00 在公司四楼会议室以现场方式召 开。本次会议应参与表决董事 8 名，实参与表决董事 8 名，公司全体高级管理人 员列席了会议。会议由董事长谢永富先生主持，会议的召开符合《中华人民共和 国公司法》（以下简称"《公司法》"）和《公司章程》的有关规定，会议合法 有效。 二、董事会会议审议情况 经充分的讨论和审议，会议以记名投票方式表决，形成如下决议： （一）会议以 8 票同意、0 票反对、0 票弃权审议通过《关于公司符合发行股 份购买资产并募集配套资金暨关联交易条件的议案》【本议案尚需提交公司股东 会审议】； 公司 ...

Group 1 - The core point of the article is that Rhine Biotech (002166.SZ) has upgraded its factory in Indiana, USA, to a comprehensive extraction facility while still maintaining its capability for CBD extraction [1] Group 2 - The company has made significant improvements to its operational capabilities through the upgrade of its facility [1] - The upgrade reflects the company's commitment to enhancing its production processes and expanding its product offerings [1] - The facility's dual capability for comprehensive extraction and CBD extraction positions the company favorably in the market [1]

Group 1 - The core point of the article is that Rhine Biotech (002166.SZ) has upgraded its factory in Indiana, USA, to a comprehensive extraction facility while still maintaining its capability for CBD extraction [1] Group 2 - The upgrade of the Indiana facility indicates a strategic move by the company to enhance its operational capabilities in the extraction sector [1] - The company continues to focus on CBD extraction, which suggests a commitment to this segment of the market [1]

Core Viewpoint - The announcement of Gulin Rhein Biotech's stock suspension due to a change in control and asset acquisition has attracted market attention, indicating significant future developments for the company [1][2]. Group 1: Control Change - The controlling shareholder, Qin Benjun, plans to transfer part of his shares to Guangzhou Defu Nutrition Investment Partnership, voluntarily relinquishing some voting rights, marking a transition to "Defu Capital Empowerment" [2][3]. - This control change is not merely a capital exchange but aligns with the strategic needs of the industry, facilitating a smooth transition that matches capital resources with industry development [3]. Group 2: Acquisition of Beijing Jinkangpu - Rhein Biotech intends to acquire 80% of Beijing Jinkangpu Food Technology Co., Ltd. through a combination of share issuance and cash payment, while simultaneously raising matching funds from Guangzhou Defu Nutrition [4][5]. - Beijing Jinkangpu, established in 2004, specializes in food nutrition fortifiers and will become a subsidiary of Rhein Biotech, enhancing the company's full industry chain layout in the food nutrition sector [4]. Group 3: Synergy and Strategic Fit - The acquisition is expected to create a synergistic effect, as Rhein Biotech's strengths in natural raw materials and formulation development will complement Beijing Jinkangpu's established market channels and customer resources [5][6]. - The collaboration aims to enhance market competitiveness by integrating Rhein Biotech's raw material advantages with Beijing Jinkangpu's market presence, ultimately leading to improved product solutions and business value [5][6]. Group 4: Transaction Details - The transaction price will be based on an assessment report from a qualified institution, with the specifics of the deal still under negotiation [6]. - The integration of Beijing Jinkangpu into Rhein Biotech's operations is anticipated to bolster the company's capabilities in the food and health product sectors, although the transaction is still subject to various approvals and uncertainties [6].

Group 1 - Action Education plans to repurchase shares worth between 20 million to 25 million yuan at a price not exceeding 45 yuan per share for employee stock ownership plans or equity incentives [1] - Fulin Technology's shareholders plan to reduce their holdings by up to 2% of the company's total shares, amounting to a maximum of 24.44 million shares starting from December 22, 2025 [2] - Huashu shares' shareholders intend to reduce their holdings by up to 1% of the company's total shares, which is a maximum of 35.94 million shares [3] Group 2 - Silan Microelectronics has obtained a filing certificate for its 12-inch high-end analog integrated circuit chip manufacturing production line project, with an investment of 10 billion yuan and a monthly production capacity of 20,000 wafers [4] - Aerospace Information confirms that its main business does not involve commercial aerospace and that its operations are normal without significant changes [5] - Qinglong Pipe Industry signed a supply contract worth 294 million yuan for PCCP and pressure steel pipes, accounting for 10.43% of its 2024 revenue [6] Group 3 - Huaxin Precision plans to invest up to 1 billion yuan of idle funds in low-risk financial products [7] - Hainan Rubber received insurance compensation totaling approximately 26.65 million yuan for rubber income and tree insurance [8] - Lianmei Holdings announced the suspension of its subsidiary Fulin Thermal Power due to economic slowdown and reduced customer demand [9] Group 4 - Ruifeng Bank has been approved to issue up to 2.5 billion yuan in secondary capital bonds to enhance its capital and risk resistance [11] - China Pacific Insurance reported a 9.4% year-on-year increase in premium income for its life insurance subsidiary, totaling 250.32 billion yuan [12] - Sunshine Nuohuo signed an agreement with Peking University to establish a joint laboratory for innovative drug development [13] Group 5 - Century Huatong completed the cancellation of 56.12 million repurchased shares, reducing its total share capital from 7.428 billion to 7.372 billion shares [14] - Yaxin Security received a government subsidy of 3 million yuan [15] - Haili Biology's subsidiary received registration certification for a bone repair material in Indonesia [16] Group 6 - Yian Technology's subsidiary secured a major project for magnesium alloy components worth 430 million yuan, expected to start production by the end of March 2026 [17] - Jiangte Electric plans to contest the proposed cancellation of its lithium-containing mining rights [18] - COFCO Technology announced the resignation of its deputy general manager due to work changes [19] Group 7 - Fangsheng Pharmaceutical passed the GMP compliance inspection for its raw material production lines [21] - Bohai Ferry announced the resignation of two deputy general managers for personal and age-related reasons [22] - ST Fuhua appointed a new general manager [23] Group 8 - Huazhong CNC received project funding of 17.7 million yuan, accounting for 31.97% of its audited net profit for 2024 [24] - Oppein Home used 15 million yuan of idle funds to purchase a large time deposit with a 0.9% annual yield [25] - China General Nuclear Power's Ningde Unit 6 has begun full construction, utilizing Hualong One technology with a capacity of 1210 MW [26] Group 9 - Jiayuan Technology's chairman has had the investigation order lifted, and the company is operating normally [27] - Fulaixin Materials' application for a specific stock issuance has been approved by the Shanghai Stock Exchange [28] - Shuhua Sports plans to invest up to 500 million yuan in a health industry park project [29] Group 10 - Rhine Biology's stock will continue to be suspended due to ongoing control change and asset acquisition plans [30] - Haishi Science received approval for clinical trials for four innovative drugs targeting various diseases [31] - Hangcai Co. plans to repurchase shares worth between 50 million to 100 million yuan at a price not exceeding 80 yuan per share [32] Group 11 - Yinxin Technology received a cash dividend of 18 million yuan from its subsidiary [33] - Tianfulong plans to increase its wholly-owned subsidiary's capital by 580 million yuan [34] - Poly United's subsidiary won a bid for a stripping project worth 1.528 billion yuan [35] Group 12 - Minglida's deputy general manager resigned due to health reasons [36] - ST Guohua appointed a new deputy general manager [37] - China Xidian's subsidiaries won contracts totaling 1.005 billion yuan for Southern Power Grid projects [38]